AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site

Published on: June 11, 2024

AGC Biologics announced the completion of a new manufacturing building at its Copenhagen, Denmark, campus in early June 2024. The expansion doubles the site’s single-use bioreactor capacity for mammalian-based services and allows the company to produce an additional 150 batches of drug product per year.

The completed project adds 19,000 m2 of space, including a large manufacturing floor, expanded quality control and process development lab space, utilities for supporting all operations and preventing outages caused by natural disasters, and a fully dedicated warehouse, according to a June 4, 2024 press release.

Read full article on

Share this page on social

Ready to get started? See what Samba can do for you.